Morgan Stanley Targets $40 Per Share Price for Kyverna Therapeutics
Monday, 4 March 2024, 07:27
Morgan Stanley Analysts Target Kyverna Therapeutics Stock
Morgan Stanley analysts have set a price target of $40 for Kyverna Therapeutics shares.
Target Reflects Growth Potential
The target reflects the potential growth and value of the company in the current market conditions.
Investment Advice
Investors are advised to consider this target when making investment decisions regarding Kyverna Therapeutics.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.